Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Kazia Therapeutics ( (KZIA) ).
Kazia Therapeutics Limited announced a change in the ratio of its American Depositary Shares (ADSs) to Ordinary Shares, effective April 17, 2025. This adjustment, equivalent to a one-for-five reverse ADS split, aims to maintain compliance with Nasdaq’s minimum bid price requirement. The change is expected to increase the ADS trading price proportionally, although no assurance is given that the price will meet or exceed expectations. The company’s Board of Directors approved this strategic move to ensure continued listing on the Nasdaq Capital Market.
Spark’s Take on KZIA Stock
According to Spark, TipRanks’ AI Analyst, KZIA is a Underperform.
Kazia Therapeutics struggles with financial instability, characterized by declining revenues, negative equity, and insufficient cash flow. These issues are compounded by a negative valuation with no dividend yield and a bearish technical outlook, all of which significantly hinder the stock’s attractiveness and growth prospects.
To see Spark’s full report on KZIA stock, click here.
More about Kazia Therapeutics
Kazia Therapeutics Limited is a biotechnology company based in Sydney, Australia, specializing in the development of innovative cancer therapies. The company focuses on advancing its pipeline of oncology drug candidates, including paxalisib, an investigational PI3K/mTOR inhibitor, and EVT801.
YTD Price Performance: -54.66%
Average Trading Volume: 1,949,741
Technical Sentiment Signal: Buy
Current Market Cap: $4.41M
For detailed information about KZIA stock, go to TipRanks’ Stock Analysis page.